Keywords
Drug therapy
Special hospitals
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the incidence of fractures in patients with osteoporosis undergoing clinical follow-up and taking zoledronic acid. Methods: Retrospective analysis of the medical records of patients with osteoporosis seen between 2019 and 2022 at an orthopedic hospital in the interior of the state of Goiás. Data from all bone densitometry (BDE) exams, the number of returns after one year from the first visit, the occurrence or not of fractures and the use of zoledronic acid and other medications were evaluated. Patients who had been followed up for two or more years were selected, and frequencies were estimated in relation to the variables: gender, age, comorbidities, BDE scans, occurrence of fracture, use of zoledronic acid and/or other medications. Results: A total of 140 patients returned to the orthopaedic hospital after one year for follow-up. The proportion of patients who returned to hospital within one year without fractures was significantly higher (p< 0.05) in those who took the drug zoledronic acid compared to those treated with other drugs. In addition to zoledronic acid, DECA (nandrolone decanoate) was the most commonly prescribed drug. Conclusion: Patients with osteoporosis, being followed up for two years or more, treated with zoledronic acid had a lower incidence of fractures compared to those treated with other drugs.
References
AZIZIYEH R, et al. A scorecard for osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. Arch Osteoporos, 2019;14(1):69.
BARBOSA AM e FERNANDES RM. Eficácia e segurança do ácido zoledrônico comparado aos bifosfonados orais para prevenção de fraturas an osteoporose: revisão rápida de evidência. Cient. Esc. Estadual Saúde Pública Goiás "Cândido Santiago". 2020;6(2):e600005.
BLACK DM, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 2007;356(18):1809-1822.
BLACK DM, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res, 2015;30(5):934-944.
BRASIL. Portaria SAS/MS nº 470, de 24 de julho de 2002, atualizada através da Portaria SAS/MS nº 451, de 9 de junho de 2014, republicada em 9 de junho de 2014 e retificada em 18 de junho de 2014. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Osteoporose. Diário Oficial da União. Brasília, 10 jun. 2014. Seção 1, p. 48. Disponível em: <http://portalarquivos.saude.gov.br/images/pdf/2014/junho/20/pcdt-osteoporose-republicadoretificado- 2014.pdf>. Acesso em: 16 jun. 2024.
BRASIL. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas da Osteoporose. Brasília, DF: Ministério da Saúde. 2022. Disponível em:<https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2022/20220919_pcdt_osteoporose.pdf>. Acesso em: 29/08/2024.
BRASIL. Ministério da Saúde. Informações de saúde: TABNET. Demográficas e socioeconômicas. Brasília, DF: Ministério da Saúde. 2024. Disponível em:<http://tabnet.datasus.gov.br/cgi/tabcgi.exe?cnes/cnv/equipobr.def>. Acesso em: 29/08/2024.
CLYNES MA et al. The epidemiology of osteoporosis. Br Med Bull, 2020;133(1):105-17.
CLYNES MA, et al. Bone densitometry worldwide: a global survey by the ISCD and IOF. Osteoporos Int, 2020a;31:1779–1786.
DAVIS S, et al. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess, 2016;20(78):i–312.
DELMAS PD, et al. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int, 2005;16(1):1-5.
DEVOGELAER JP, et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int. 2007;18:1211-18.
FINK HA, et al. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Ann Intern Med, 2019;171(1):37-50.
FOESSL, I., et al. Long-term and sequential treatment for osteoporosis. Nat Rev Endocrinol. 2023;19(9):520-33.
FÖGER-SAMWALD U, et al. Osteoporosis: pathophysiology and therapeutic options. Excli J, 2020;19:1017-1037.
GREGSON CL, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos, 2022;17(1):58.
JIA F, et al. The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis. Biomaterials, 2023;296,122059.
KONG L, et al. Clinical effect of zoledronic acid in the treatment of senile osteoporosis. Pakistan Journal of Medical Sciences, 2020; 36(7), 1703.
LYLES KW, et al. Zoledronic acid reduces the rate of clinical fractures after surgical repair of a hip fracture regardless of the pretreatment bone mineral density. Osteoporos Int 2021;32:1217-9.
MARIANA JR e MARCONDES AL. Análise do número de equipamentos de densitometria óssea no brasil para diagnóstico de osteoporose. Tekhne e Logos. 2022;13(1),109-18.
MORI T, et al. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan. Archives of osteoporosis, 2021;16, 1-14.
PALUI R, et al. Timing of osteoporosis therapies following fracture: the current status. Ther Adv Endocrinol Metab. 2022; 13:1-19.
RADOMINSKI SC, et al. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós‐menopausa. Rev Bras Reumatol. 2017;57(S 2):452–66.
REID IR, et al. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res. 2020;35:20–27.
RIBEIRO GM, et al. A importância do exame de densitometria óssea para o diagnóstico e tratamento da osteoporose. Rev Interdisc Meta.2023;1(1),13–25.
SABRI SA, et al. Osteoporosis: An Update on Screening, Diagnosis, Evaluation, and Treatment. Orthopedics, 2023;46(1):e20-e26.
SALARI N, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res, 2021;16(1):609.
SIMPSON EL, et al. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis. Bone, 2020;130:115081.
WANG B, et al. How zoledronic acid improves osteoporosis by acting on osteoclasts. Frontiers in Pharmacology, 13, 2022; 961941.
WU TC, et al. Five-year outcomes of continuous treatment with zoledronic acid versus denosumab in older men with high fracture risk: risk factor analysis of bone density improvement and incidence of new fracture. J Clin Pharmacol. 2024;64(4):469-77.
YOSHIZAWA S, et al. Zoledronic acid for osteoporosis after distal radius fracture surgery. Journal of Orthopaedics, 43, 109-114.